MARS: mutation-adjusted risk score for advanced systemic mastocytosis
1 ビュー
• 07/09/23
0
0
埋め込む
administrator
加入者
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント